Seattle Genetics (SGEN), a biotechnology company, said pre-market Wednesday that it has started dosing of a first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma (MM).
SGN-CD48A uses the company’s latest ADC technology advancement, a PEGylated glucuronide linker that improves stability and reduces off-target uptake.
Multiple myeloma is the second most common blood cancer in the US and remains an incurable disease despite recent medical advances, according to the statement.
“SGN-CD48A uses our latest ADC technology, and the initiation of this phase 1 trial in relapsed or refractory multiple myeloma highlights our continued leadership in ADCs as we address this challenging disease.” lead investigator Robert Lechleider said in a statement.
The phase 1 study is a multicenter open-label dose-escalation trial designed to enroll approximately 75 patients with relapsed or refractory MM.